Confirmed Sponsors & Exhibitors

Confirmed Sponsors & Exhibitors

Thank you to our sponsors and exhibitors for supporting the 4th Annual Congress of Liquid Biopsy (ISLB 2022)




Foundation Medicine




Thermo Fisher

Menarini Silicon Biosystems


Sermonix Pharmaceuticals

Bio-Rad Laboratories

Blueprint Medicines



ANGLE is a world-leading liquid biopsy company with offices in Guildford (UK), Toronto (Canada) and Greater Philadelphia (USA). ANGLE’s Parsortix® PC1 Clinical System is the first

FDA cleared medical device for the capture and harvest of intact circulating tumor cells from metastatic breast cancer patient blood for subsequent, user-validated analysis. (

Tell me more


Biodesix’ mission is to unite biopharma, physicians, and patients to transform the standard of care and improve outcomes with personalized diagnostics. We envision a world where all critical diseases are diagnosed early and treated quickly with the guidance of personalized diagnostic solutions, so humanity can thrive without the burden of disease. (

Bio-Rad Laboratories

Bio-Rad is a global leader for life science research and clinical diagnostics that advance several applications for liquid biopsy. For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification. Celselect Slide™ Technology with the Genesis System enables CTC enrichment and enumeration applications. (


BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. (

Caris Life Sciences

Caris Life Sciences® is the leading molecular science and technology company developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins, revealing a molecular blueprint helping physicians better detect, diagnose and treat patients. (

Foundation Medicine

Foundation Medicine’s highly validated portfolio of comprehensive genomic profiling tests provides clinically-relevant genomic results for all advanced cancer patients regardless of specimen type. Find out more about the first FDA-approved test for solid tumors, our liquid biopsy for solid tumors, and our test for hematologic malignancies at

Tell me more


Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. (

Menarini Silicon Biosystems

Menarini Silicon Biosystems’ new Circulating Multiple Myeloma Cell (CMMC) Assay captures and enumerates CMMCs from peripheral blood and provides a minimally invasive tool to study multiple myeloma and precursor disease states. Through groundbreaking technology and global lab services, we have standardized serial monitoring through cell-based liquid biopsy for many conditions. (


Signatera is a personalized, tumor-informed ctDNA assay for molecular residual disease (MRD) detection and treatment response monitoring in patients previously diagnosed with cancer. Signatera is optimized to detect low levels of ctDNA, to help stratify high risk patients and optimize patient management. Discover more at: (


Data-driven precision medicine.Bringing the power of data and artificial intelligence to healthcare. (

Tethis S.p.A.

Tethis S.p.A. introduces automation and standardization in the pre-analytical phase of liquid biopsy for cancer diagnostics through its proprietary platform See.d and SBS nanocoated slides, providing the highest quality and integrity of liquid biopsy specimens (plasma and cellular fraction), and enabling the exploitation of multi-biomarkers analysis for precise cancer management. (


Dr. Oloriz, 16 Street
CP 18012 Granada - Spain

+43 1 3950 6191
(when asked for extension please enter: 303)

Privacy policy


© 2022 - ISLB | designed & powered by publics iCC